Regencell Bioscience Holdings (Regencell Bioscience Holdings) Equity-to-Asset

: 0.95 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Regencell Bioscience Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $12.03 Mil. Regencell Bioscience Holdings's Total Assets for the quarter that ended in Jun. 2023 was $12.62 Mil.

The historical rank and industry rank for Regencell Bioscience Holdings's Equity-to-Asset or its related term are showing as below:

RGC' s Equity-to-Asset Range Over the Past 10 Years
Min: -11.76 Med: -5.16 Max: 0.95
Current: 0.95

During the past 5 years, the highest Equity to Asset Ratio of Regencell Bioscience Holdings was 0.95. The lowest was -11.76. And the median was -5.16.

RGC's Equity-to-Asset is ranked better than
98.07% of 1086 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs RGC: 0.95

Regencell Bioscience Holdings Equity-to-Asset Historical Data

The historical data trend for Regencell Bioscience Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Equity-to-Asset

-7.57

-5.16

-11.76

0.95

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Equity-to-Asset	Get a 7-Day Free Trial				-11.76	0.94	0.95	0.94	0.95

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings Equity-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Equity-to-Asset falls into.

Regencell Bioscience Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Regencell Bioscience Holdings's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	12.03	/	12.622
	=

Regencell Bioscience Holdings's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	12.03	/	12.622
	=

Regencell Bioscience Holdings (NAS:RGC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Regencell Bioscience Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.